Jing-Wen Chen Wen-Shuang Zhang Chang-Song Lin Qiang Xu
10.3389/fimmu.2022.1074329
Front Immunol
2022 Dec 14;13:1074329.
jaki tnfi adalimumab dual therapy rheumatoid arthritis tofacitinib
CC BY
https://pubmed.ncbi.nlm.nih.gov/36591263/
Antirheumatic Agents / therapeutic use Arthritis, Rheumatoid / diagnosis Arthritis, Rheumatoid / drug therapy Biological Products / therapeutic use
Antirheumatic Agents / therapeutic use Arthritis, Rheumatoid / diagnosis Arthritis, Rheumatoid / drug therapy Biological Products / therapeutic use Case Reports Adalimumab / therapeutic use Female Humans Methotrexate / therapeutic use Middle Aged Tumor Necrosis Factor-alpha Methotrexate Adalimumab Biological Products Antirheumatic Agents Tumor Necrosis Factor-alpha
PMC9794839
36591263
Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
2022